Our Board


Steve Beard

Chief Practice Officer: HTA & Reimbursement Consulting

Steve joined BresMed as a member of the Board in 2013. After gaining his post-graduate qualifications in Operational Research, Steve applied modelling techniques in both the manufacturing and finance sectors, before moving into the emerging field of health economics; first at the School of Health and Related Research (ScHARR) at the University of Sheffield, before joining RTI Health Solutions to lead and develop their European team of 40+ health economics and outcomes research (HEOR) consultants. At BresMed, Steve’s specific responsibility is for the Health Technology Assessment (HTA) and Reimbursement practice area. He drives the overall technical and consulting excellence and business development within this team, and works with the rest of the Board to define and deliver on BresMed’s strategic direction.

In his spare time, Steve plays hockey for Sheffield Hallam HC, and heads to Anfield to watch Liverpool FC play whenever he can.

What Steve says about BresMed: “What sets BresMed apart from other companies is our ability to really connect with our clients in terms of their commercial needs and objectives, using this as a firm basis to all our collaborations and partnerships.”

Curriculum vitae

Employment history

2018-Present   Chief Practice Officer: HTA & Reimbursement Consulting   BresMed

2013-2018   Director of Business Development   BresMed

2012-2013   Vice President of Business Development   RTI Health Solutions

2002-2012   Vice President, Health Economics (European Operations)   RTI Health Solutions

2000-2002   Senior Health Economist   RTI Health Solutions

1996-2000   Senior Health Economic Modeller   School of Health and Related Research (ScHARR), The University of Sheffield


Research areas of interest

Has spent over 25 years in a senior consulting role, developing and leading teams in providing strategic and health economic guidance and submission advice to clients within the pharmaceutical and medical devices industry. A keen research interest in the effective application of HTA analytical evaluation, with a core skill set covering market access value demonstration, decision analytic modelling, and statistical analysis; with a particular interest in setting best practices in how to plan, coordinate and dynamically manage complex strategically-impacting multidisciplinary HEOR projects.


Therapeutic areas of expertise

  • Gout / Chronic Hyperuricaemia – Led the health economic model development and provided strategic advice in developing a value argumentation for a product in treating chronic gout. This resulted in a limited NICE approval for second line use, following appeal, and a successful second line positioning from the SMC
  • Hepatitis C – development of economic models evaluating anti-viral treatments and platelet treatments to support active management of HCV
  • Venous Thromboembolism – Provided strategic advice and health economic modelling oversight in the development of an economic model and a successful submission strategy for the prevention of VTE (involved submissions to NICE, SMC, CADTH and NCPE)
  • Overactive Bladder – Developed a standard decision-tree based model and led a systematic evidence review for the evaluation of a new product in the treatment of overactive bladder, and contributed as part of a successful SMC submission team
  • Multiple Sclerosis – Provided modelling expertise into a wider team designing and conducting a full systematic review and economic model adaptation to support a NICE STA. This involved a PAS as part of a limited reimbursement approval
  • Chronic Idiopathic Urticaria (CIU) – Led the development of a full HTA economic evaluation for a new product in CIU, involving a full systematic clinical and economic review and a full Markov model based approach, to support an anticipated NICE STA
  • Psoriasis – Led the development of a full HTA economic evaluation for a new product in psoriasis, involving a MTC and a full Markov model based approach, to support a NICE STA
  • Diabetic Peripheral Neuropathic Pain – Led the development of a full HTA economic evaluation which was used as part of a SMC submission and a submission to CADTH as part of the CDR process in Canada
  • Chronic Idiopathic Thrombocytopenia Purpura – Led the development of a full Markov based model for the treatment of ITP, which was used to prepare a submissions to NICE and CADTH
  • HIV – Treatment evaluation and clinical management strategies for early diagnosis and initiation of treatment
  • Fibromyalgia – development of economic models to establish value against off-label comparators (such as TCA antidepressants)



View Steve’s publication history in our database


Referee/Reviewer roles

  • Journal of Applied Health Economics and Health Policy (Editorial Board)
  • Reviewer for Pharmacoeconomics
  • Reviewer for AHEHP


Back to Our Board